{
  "id": 14037822,
  "title": "StockWatch: Caribou Plunges as It Pursues Strategic Alternatives",
  "url": "https://urgent.news/2026/10/12/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T19:48:28.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/genome-editing/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives/"
  },
  "original_language": "en",
  "account": "Caribou Biosciences' stock price plummeted 62% over the course of a week after the company announced plans to explore alternative strategies. The biotech firm, co-founded by Jennifer Doudna, experienced an 83% drop in stock value over the past year. The company is reducing its workforce by an unspecified \"substantial\" amount, currently numbering 97 employees, and ceasing trials of its two clinical-phase pipeline candidates, CB-010 and CB-011, which are allogeneic chimeric antigen receptor (CAR) T-cell therapies for B cell non-Hodgkin lymphoma and multiple myeloma, respectively. Co-founder and CEO Rachel Haurwitz explained that the decision had nothing to do with the company's scientific merits or clinical data. The financial climate for allogeneic CAR T-cell therapies has made it challenging to secure the necessary capital to advance these programs.",
  "summary": "Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma. The post StockWatch: Caribou Plunges as It Pursues Strategic Alternatives appeared first on GEN - Genetic Engineering and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}